Vivozon Secured Patents for Non-Opioid Analgesic
The company obtained intellectual property rights for its painkiller candidate in South Korea and Israel.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Do you trust non-opioid drug developments to address addiction risks in pain management?
Biotech firm Vivozon has secured new patent registrations for its non-opioid oral analgesic candidate, VVZ-2471. These protections cover a core group of 125 compounds.
Why it matters
The development aims to provide an alternative to traditional pain medications by addressing the addiction and tolerance risks commonly associated with opioid-based analgesics.
The patent registrations cover a specific group of 125 compounds designed for VVZ-2471. This drug candidate functions through a dual mechanism targeting mGluR5 and 5-HT2A receptors.
The players
Vivozon
Vivozon is a biotechnology company focused on developing novel non-opioid analgesic medications to address chronic pain.
The details
VVZ-2471 is designed as an oral, non-opioid drug meant to treat pain while avoiding the side effects found in existing opioids. Vivozon has already reached Phase 2 dosing for postherpetic neuralgia in South Korea and maintains Investigational New Drug approval in the United States.
Timeline
Vivozon announced the South Korea and Israel patent registrations on September 21, 2026.
The Tech Race
This patent acquisition follows the wider industry movement to replace traditional opioid-heavy pain management systems with targeted, receptor-based therapies. It positions Vivozon within a competitive landscape of firms seeking to solve the long-standing clinical challenge of opioid dependence.
The advancement of non-opioid alternatives could eventually change how patients access pain relief without the risks of addiction. For now, users must wait for the company to proceed with domestic Phase 2 trials and U.S.-based investigator-led studies.
The takeaway
The move to secure international patent rights is a strategic step toward commercializing a safer pain management alternative. Patients and providers should monitor upcoming clinical trial results as the company works to transition the candidate from the laboratory to the market.
Further reading
Learn more about the latest innovations in the field within the Biotech section.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you trust non-opioid drug developments to address addiction risks in pain management?
